NuCana plc (NASDAQ:NCNA) Short Interest Up 321.8% in September

NuCana plc (NASDAQ:NCNA) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 263,600 shares, a growth of 321.8% from the September 15th total of 62,500 shares. Approximately 12.5% of the shares of the company are short sold. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of NuCana

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc bought a new position in shares of NuCana plc (NASDAQ:NCNA) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana at the end of the most recent quarter. Institutional investors and hedge funds own 44.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NCNA shares. Oppenheimer cut their price objective on NuCana from $150.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, September 3rd. William Blair cut NuCana from an “outperform” rating to a “market perform” rating in a report on Friday, August 30th.

NuCana Trading Down 0.5 %

Shares of NuCana stock traded down $0.01 during trading on Thursday, reaching $2.16. The company’s stock had a trading volume of 129,482 shares, compared to its average volume of 490,779. The stock has a 50-day moving average price of $3.91 and a two-hundred day moving average price of $3.89. NuCana has a one year low of $1.86 and a one year high of $20.25. The stock has a market capitalization of $5.71 million, a P/E ratio of -0.19 and a beta of 1.00.

NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Thursday, August 15th. The company reported ($3.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.55) by ($0.24). As a group, sell-side analysts anticipate that NuCana will post -13.86 EPS for the current fiscal year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.